Ferric Carboxymaltose in Type 2 Diabetes Mellitus (T2DM) Patients With Iron Deficiency
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 152 participants.
Also called NCT01513369
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 152 participants
- Sponsor
- GWT-TUD GmbH
- Registry
-
NCT01513369 -
2011-005224-18
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Germany
- Registry status
- Completed
Technical summary
Registry record NCT01513369. Randomized; single masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2018-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ferric Carboxymaltose in Type 2 Diabetes Mellitus (T2DM) Patients With Iron Deficiency
- Acronym
- CLEVER
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Iron Deficiency
- Intervention (Drug)
- ferric carboxymaltose
- Intervention (Drug)
- NaCl (0,9%)
- Lead sponsor
- GWT-TUD GmbH
- Collaborator
- Vifor Pharma
Record details
- Record id
cardio:ct-nct01513369- Content hash
521678796ab2088598cf3150a8aad4347774e0701831096fd7f05d5ebd9f8043